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Autoimmune conditions are associated with an elevated risk of lymphoproliferative malignancies, but few studies have investigated
the risk of myeloid malignancies. From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13486 myeloid
malignancy patients (aged 67þ years) and 160086 population-based controls were selected. Logistic regression models adjusted for
gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for myeloid malignancies in
relation to autoimmune conditions. Multiple comparisons were controlled for using the Bonferroni correction (Po0.0005).
Autoimmune conditions, overall, were associated with an increased risk of acute myeloid leukaemia (AML) (OR 1.29) and
myelodysplastic syndrome (MDS, OR 1.50). Specifically, AML was associated with rheumatoid arthritis (OR 1.28), systemic lupus
erythematosus (OR 1.92), polymyalgia rheumatica (OR 1.73), autoimmune haemolytic anaemia (OR 3.74), systemic vasculitis (OR
6.23), ulcerative colitis (OR 1.72) and pernicious anaemia (OR 1.57). Myelodysplastic syndrome was associated with rheumatoid
arthritis (OR1.52) and pernicious anaemia (OR 2.38). Overall, autoimmune conditions were not associated with chronic myeloid
leukaemia (OR 1.09) or chronic myeloproliferative disorders (OR 1.15). Medications used to treat autoimmune conditions, shared
genetic predisposition and/or direct infiltration of bone marrow by autoimmune conditions, could explain these excess risks of
myeloid malignancies.
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The aetiology of myeloid malignancies, a heterogeneous group of
disorders including acute myeloid leukaemia (AML), chronic
myeloid leukaemia (CML), myelodysplastic syndrome (MDS) and
chronic myeloproliferative disorders (MPDs), remains largely
unknown. The main risk factors identified for AML are cigarette
smoking (Kasim et al, 2005; Xu et al, 2007) and exposure to
benzene or ionising radiation (Descatha et al, 2005). Chronic
myeloid leukaemia arises from a translocation t(9;22)(q34;q11),
known as the Philadelphia chromosome, and is thought to be
associated with radiation exposure (Preston-Martin et al, 1989).
Myelodysplastic syndrome is a heterogeneous clonal haematolo-
gical disorder that can progress to AML. Cigarette smoking (Nisse
et al, 2001), solvent exposure (Nisse et al, 2001) and agricultural
exposures (Strom et al, 2005) have all been associated with an
increased risk of MDS, and senescence of the haematopoietic
system is thought to play a role in its development (Dalamaga et al,
2002). Less is known about the causes of MPDs, including
polycythemia vera and essential thrombocythemia.
Immune perturbations, including autoimmune diseases, have
been associated with an increased risk of haematological
malignancies. Although reported more commonly for lymphopro-
liferative neoplasms (Zintzaras et al, 2005; Ekstrom Smedby et al,
2008), increased risks in persons with autoimmune conditions
have also been noted for myeloid malignancies, including AML
and CML (Zheng et al, 1993; Askling et al, 2005b). Autoimmune
conditions, which occur commonly in patients with MDS
(Voulgarelis et al, 2004), have also been reported to precede
MDS (Dalamaga et al, 2002). Using data from the Surveillance
Epidemiology and End Results (SEER)-Medicare Assessment of
Hematopoietic Malignancy Risk Traits (SMAHRT) study, we
investigated whether autoimmune conditions were associated with
subsequent risks of AML, CML, MDS and MPDs.
MATERIALS AND METHODS
The SMAHRT study is a population-based case–control study of
haematopoietic malignancies using SEER-Medicare data (Warren
et al, 2002; Anderson et al, 2008). The SEER program collects data
on cancer diagnoses from multiple US sites since 1973 and
currently covers B25% of the US population (Warren et al, 2002).
Medicare provides federally funded health insurance for persons
aged 65 years and older in the United States. All Medicare
beneficiaries are entitled to Part A coverage, which includes
hospital inpatient care. Approximately 96% of participants
subscribe to Part B coverage, which covers both physician and
outpatient services. The SEER-Medicare database has demographic
and clinical information from SEER on cancer patients through
December 2002, linked to their Medicare enrolment and claims
data (Part A claims: 1986–2002; Part B claims: 1991–2002)
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y(Warren et al, 2002). In addition, the Medicare data are available
for a 5% random sample of all Medicare beneficiaries without
cancer residing in SEER areas.
The SMAHRT study includes, as cases, those individuals with a
SEER diagnosis of a first primary haematopoietic malignancy
(n¼93780) between 1987 and 2002. We restricted this analysis to
persons with a myeloid malignancy (n¼13486). Cases were
classified into the following categories: AML (ICD-03 codes: 9840,
9861, 9866, 9867, 9870–9874, 9891, 9895–9897, 9910, 9920, 9930,
9931), CML (ICD-03: 9863, 9875, 9876), MDS (ICD-03: 9945, 9980,
9982, 9983, 9985, 9986, 9989) and MPD (ICD-03: 9741, 9742, 9750,
9754, 9755, 9756, 9757, 9950, 9960, 9961–9964, 9975). As MDS and
MPD were not reportable to SEER registries until 2001 (Jaffe et al,
2001), only cases diagnosed in 2001 and 2002 were included
(n¼2471 and n¼1017, respectively). Cases were required to be
aged 67–99 years at diagnosis of malignancy and to have at least
12 months of Part A, Part B and non-HMO Medicare coverage
before diagnosis to ensure adequate time for accrual of Part A (and
where applicable Part B) Medicare claims to ascertain the
occurrence of autoimmune conditions. Persons diagnosed with
malignancy only at autopsy or by a death certificate and those with
human immunodeficiency virus infection were excluded.
The SMAHRT study includes two controls per haematopoietic
malignancy case, selected from the 5% random sample of Medicare
beneficiaries who were alive, free of any malignancy, and had at
least 12 months of prior Medicare coverage as of 1 July in the
calendar year of selection. Controls were frequency matched to
haematopoietic malignancy cases by the calendar year of
diagnosis, age in five categories (67–69, 70–74, 75–79, 80–84
and 85–99 years) and gender. A person could be selected multiple
times as a control for cases in different calendar years. All the
SMAHRT study controls (n¼160086) were included in the AML
and CML analyses. Only controls selected in 2001 and 2002
(n¼42886) were included in the MDS and MPD analyses.
We used hospital, physician and outpatient Medicare claims to
assess whether individuals had any of the 27 specified autoimmune
conditions (see Table 2). In assessing exposures, we required that
the autoimmune condition was specified on at least one hospital
claim, or at least two-physician or outpatient claims at least 30
days apart. Claims occurring during the 12-month period before
case diagnosis–control selection were excluded to minimise the
possibility that diagnoses of autoimmune conditions would be
over-represented in cases because of ascertainment during the
work-up for the malignancy.
Statistical analysis
Unconditional logistic regression was used to calculate the odds
ratios (ORs) and 95% confidence intervals (CIs), to assess the
association of autoimmune conditions with myeloid malignancies
separately for cases of each type compared with that in controls.
We accommodated in the variance computation for the ORs the
fact that each case subtype was compared with the same control
population, that some controls later served as cases and the repeat
selection of individuals as controls (Anderson et al, 2008). The
AML and CML analyses were adjusted for age (using the categories
of 67–69, 70–74, 75–79, 80–84, and 85–99 years), gender, year of
diagnosis/selection (1987–1996, 1997–1999, 2000–2001, 2002),
race (white, other/unknown) and, as a measure of overall
healthcare utilisation, the number of physician claims more than
12 months before diagnosis/selection (quartiles: 0–20, 21–57, 58–
127, X128). The MDS and MPD analyses were adjusted for the
same factors, except that the year of diagnosis/selection was
included in models as two categories (2001 and 2002). As some
myeloid malignancies, particularly MDS and MPD, can be chronic
conditions, we conducted additional analyses excluding the 2 and 5
years before the diagnosis date of cases and the selection date of
controls to ensure that the autoimmune conditions preceded MDS
and MPD.
As we conducted 108 separate analyses to investigate the
associations between 27 autoimmune conditions and 4 myeloid
malignancies, we considered the impact of multiple testing on our
findings. Although we indicate associations significant at a
nominal significance level of P¼0.05, we especially highlight in
the tables and in the Discussion section those associations that
were significant at a P-value of 0.0005, which incorporates a
Bonferroni correction.
RESULTS
This study included 13486 cases with a myeloid malignancy, which
comprised 7824 individuals with AML, 2174 with CML, 2471 with
MDS and 1017 with MPD. Compared with controls, cases were
more likely to be male (except for MPD, in which cases were more
likely to be female) and of white race. The median age at diagnosis/
selection was similar for the myeloid malignancy cases and
controls. For each myeloid neoplasm, cases had more prior
physician, outpatient and hospital claims than controls (Table 1).
As shown in Table 2, having any autoimmune condition was
associated with an increased risk of AML (OR 1.29). Specifically,
AML was associated positively with several autoimmune condi-
tions at the Po0.05 significance level, including rheumatoid
arthritis (OR 1.28), systemic lupus erythematosus (OR 1.92),
polymyalgia rheumatica (OR 1.73), autoimmune haemolytic
anaemia (AIHA) (OR 3.74), systemic vasculitis (OR 6.23), giant
cell arteritis (OR 1.61), ulcerative colitis (OR 1.72) and pernicious
anaemia (OR 1.57). Chronic myeloid leukaemia was increased with
polymyalgia rheumatica (OR 1.79), dermatomyositis/polymyositis
(OR 3.97), AIHA (OR 5.23) and coeliac disease (OR 4.19) (Table 2).
Overall, MDS was associated with having an autoimmune
condition (OR 1.50) and specifically with rheumatoid arthritis
(OR 1.52), Sjo ¨gren’s syndrome (OR 1.78), systemic lupus
erythematosus (OR 1.82), polymyalgia rheumatica (OR 1.47),
AIHA (OR 4.12), chronic rheumatic heart disease (OR 1.28),
polyarteritis nodosa (OR 4.31), discoid lupus erythematosus (OR
2.06) and pernicious anaemia (OR 2.38). In comparison, MPD was
only associated with AIHA (OR 11.9), localised scleroderma (OR
2.34) and Crohn’s disease (OR 2.18).
As MDS and MPD are often chronic diseases that may go
unrecognised for several years, we conducted a sensitivity analysis
excluding claims within 2 or 5 years of diagnosis. Compared with
controls, MDS cases more commonly had rheumatoid arthritis
(OR 1.52), polymyalgia rheumatica (OR 1.53) and pernicious
anaemia (OR 1.68) reported more than 5 years before the
diagnosis/selection (Table 3). Similiarly, localised scleroderma
remained associated significantly with MPD when the 2-year or
5-year period before diagnosis was excluded (ORs 2.73 and 3.27,
respectively) (Table 3).
Associations that remained significant after using a Bonferroni
correction (Po0.0005) are highlighted in Table 2. These included
rheumatoid arthritis, systemic lupus erythematosus, polymyalgia
rheumatica, AIHA, systemic vasculitis, ulcerative colitis and
pernicious anaemia with AML; dermatomyositis/polymyositis with
CML; rheumatoid arthritis and pernicious anaemia with MDS; and
AIHA with MPD.
DISCUSSION
In this large study of 13486 individuals with a myeloid
malignancy, we investigated systematically the associations with
a range of preceding autoimmune conditions. Overall, having an
autoimmune condition was associated with an increased risk of
AML and MDS, but not CML or MPD. Given the large number of
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ycomparisons, we focus here on associations that were significant at
a P-value cutoff provided by the Bonferroni method (Po0.0005).
We observed significantly increased risks of AML and MDS
associated with rheumatoid arthritis. Supporting this observation,
Askling et al (2005b) found two-fold increased risks of AML and
CML in a large Swedish cohort study of patients hospitalised for
rheumatoid arthritis. Although MDS is a chronic condition, we saw
an association with rheumatoid arthritis even after excluding the
5-year period before diagnosis/selection, arguing against reverse
causality (i.e., that undiagnosed MDS caused rheumatoid arthritis).
Table 1 Characteristics of cases with myeloid malignancies and controls in the SMAHRT study





















Male 78620 (49.1%) 4156 (53.1%) 1122 (51.6%) 21460 (50.0%) 1339 (54.2%) 457 (44.9%)
Female 81466 (50.9%) 3668 (46.9%) 1052 (48.4%) 21426 (50.0%) 1132 (45.8%) 560 (55.1%)
Age, years
67–69 19135 (12.0%) 893 (11.4%) 278 (12.8%) 4085 (9.5%) 156 (6.3%) 95 (9.3%)
70–74 40611 (25.4%) 1957 (25.0%) 501 (23.1%) 9788 (22.8%) 472 (19.1%) 232 (22.8%)
75–79 41724 (26.1%) 2050 (26.2%) 546 (25.1%) 11330 (26.4%) 651 (26.4%) 285 (28.0%)
80–84 32091 (20.1%) 1627 (20.8%) 433 (19.9%) 9742 (22.7%) 654 (26.5%) 239 (23.5%)
85–99 26525 (16.6%) 1297 (16.6%) 416 (19.1%) 7941 (18.5%) 538 (21.8%) 166 (16.3%)
Median (range) 77 (67–99) 77 (67–99) 77 (67–99) 78 (67–99) 78 (67–99) 79 (67–99)
Selection year
1987–1996 71396 (44.6%) 3355 (42.9%) 1173 (54.0%) — — —
1997–1999 26946 (16.8%) 1411 (18.0%) 324 (14.9%) — — —
2000 40750 (25.5%) 2105 (26.9%) 484 (22.3%) — — —
2001–2002 20994 (13.1%) 953 (12.2%) 193 (8.9%) 42886 (100%) 2471 (100%) 1017 (100%)
Race/ethnicity
White 135280 (84.5%) 6912 (88.3%) 1900 (87.4%) 35959 (83.9%) 2173 (87.9%) 875 (86.0%)
Black 10897 (6.8%) 386 (4.9%) 148 (6.8%) 2973 (6.9%) 156 (6.3%) 85 (8.4%)
Asian 5629 (3.5%) 160 (2.0%) 39 (1.8%) 1689 (3.9%) 62 (2.5%) 21 (2.1%)
Hispanic 3408 (2.1%) 88 (1.1%) 31 (1.4%) 1157 (2.7%) 40 (1.6%) 19 (1.9%)
Native American
Indian
448 (0.3%) 7 (0.1%) 4 (0.2%) 111 (0.3%) 5 (0.2%) 2 (0.2%)
Other/unknown 4424 (2.8%) 271 (3.5%) 52 (2.4%) 997 (2.3%) 35 (1.4%) 15 (1.5%)
Duration of Medicare coverage
c
13–57 months 62264 (38.9%) 2186 (36.0%) 919 (42.3%) 10208 (23.8%) 453 (18.3%) 228 (22.4%)
58–93 months 36842 (23.0%) 1794 (22.9%) 504 (23.2%) 7312 (17.1%) 360 (14.6%) 163 (16.0%)
94–136 months 30696 (19.2%) 1704 (21.8%) 430 (19.8%) 8571 (20.0%) 450 (18.2%) 204 (20.1%)
X137 months 30284 (18.9%) 1510 (19.3%) 321 (14.8%) 16795 (39.2%) 1208 (48.9%) 422 (41.5%)
Number of physician claims
d
0–20 68324 (42.7%) 2931 (37.5%) 952 (43.8%) 8285 (19.3%) 280 (11.3%) 143 (14.1%)
21–57 30532 (19.1%) 1329 (17.0%) 382 (17.6%) 7949 (18.5%) 307 (12.4%) 199 (19.6%)
58–127 30763 (19.2%) 1548 (19.8%) 381 (17.5%) 10843 (25.3%) 568 (23.0%) 272 (26.8%)
X128 30467 (19.0%) 2016 (25.8%) 459 (21.1%) 15809 (36.9%) 1316 (53.3%) 403 (39.6%)
Number of outpatient claims
d
0 62453 (39.0%) 2736 (35.0%) 880 (40.5%) 7323 (17.1%) 253 (10.2%) 109 (10.7%)
1–3 32154 (20.1%) 1405 (18.0%) 403 (18.5%) 8404 (19.6%) 332 (13.4%) 164 (16.1%)
4–7 21293 (13.3%) 1042 (13.3%) 278 (12.8%) 7005 (16.3%) 339 (13.7%) 163 (16.0%)
8–15 20722 (12.9%) 1106 (14.1%) 256 (11.8%) 8242 (19.2%) 498 (20.2%) 190 (18.7%)
X16 23464 (14.7%) 1535 (19.6%) 357 (16.4%) 11912 (27.8%) 1049 (42.5%) 391 (38.5%)
Number of hospital claims
d
0 87059 (54.4%) 3658 (46.8%) 1001 (46.0%) 20058 (46.8%) 803 (32.5%) 443 (43.6%)
1 28505 (17.8%) 1533 (19.6%) 419 (19.3%) 7623 (17.8%) 449 (18.2%) 199 (19.6%)
2–3 25255 (15.8%) 1447 (18.5%) 412 (19.0%) 7779 (18.1%) 561 (22.7%) 169 (16.6%)
X4 19267 (12.0%) 1186 (15.2%) 342 (15.7%) 7426 (17.3%) 658 (26.6%) 206 (26.6%)
SMAHRT¼Surveillance Epidemiology and End Results (SEER)-Medicare Assessment of Hematopoietic Malignancy Risk Traits.
aThis category includes patients with refractory
anaemia, refractory cytopenia with multilineage dysplasia, myelodysplastic syndrome with 5q deletion and myelodysplastic syndrome, not otherwise specified, diagnosed during
2001–2002.
bThis category includes patients with chronic neutrophilic leukaemia, chronic esinophilic leukaemia, chronic myeloproliferative disease not otherwise specified,
chronic idiopathic myelofibrosis, essential thrombocythemia, polycythemia vera, mastocytosis and neoplasms of histiocytes and accessory lymphoid cells diagnosed during
2001–2002.
cDuration of coverage refers to simultaneous coverage by Part A and Part B while the individual was not enroled in a health maintenance organisation.
dThe number
of claims excludes the 12 months before haematopoietic malignancy diagnosis (cases) or selection (controls).
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yTable 2 Associations between autoimmune conditions and risk of myeloid malignancies














conditions No. No. OR (95% CI)
a No. OR (95% CI)
a No. No. OR (95% CI)









3425 237 1.28 (1.11–1.47)
c 56 1.23 (0.94–1.62) 1480 150 1.52 (1.27–1.81)
c 39 1.01 (0.73–1.41)
Sjo ¨gren’s syndrome 261 16 1.10 (0.66–1.82) o5 1.14 (0.42–3.09) 120 15 1.78 (1.03–3.07) o5 0.90 (0.29–2.85)
Systemic lupus
erythematosus
298 31 1.92 (1.31–2.80)
c 5 1.28 (0.52–3.12) 117 14 1.82 (1.04–3.16) o5 0.31 (0.04–2.23)
Sarcoidosis 101 10 1.84 (0.95–3.56) o5 0.76 (0.11–5.46) 42 o5 1.11 (0.34–3.61) 0 —
Systemic sclerosis 83 o5 0.90 (0.33–2.47) o5 0.94 (0.13–6.80) 38 5 2.05 (0.80–5.25) o5 0.93 (0.13–6.85)
Polymyalgia
rheumatica
1288 125 1.73 (1.43–2.09)
c 32 1.79 (1.25–2.57) 518 55 1.47 (1.11–1.96) 15 1.11 (0.66–1.86)
Ankylosing
spondylitis
133 11 1.43 (0.76–2.68) o5 0.53 (0.07–3.84) 59 5 1.18 (0.47–2.93) o5 2.04 (0.64–6.55)
Dermatomyositis/
polymyositis
135 7 0.91 (0.42–1.96) 7 3.97 (1.82–8.61)




52 11 3.74 (1.94–7.22)
c o5 5.23 (1.82–15.0) 20 6 4.12 (1.66–10.2) 6 11.9 (4.72–30.2)
c
Cardiovascular
Systemic vasculitis 27 10 6.23 (2.81–13.8)
c 0— 8 o5 3.49 (0.71–17.0) 0 —
Chronic rheumatic
heart disease
4099 239 1.01 (0.88–1.15) 57 0.99 (0.76–1.30) 1839 173 1.28 (1.08–1.51) 46 0.98 (0.73–1.33)
Giant cell arteritis 427 37 1.61 (1.14–2.27) o5 0.36 (0.09–1.44) 171 16 1.28 (0.76–2.16) o5 0.44 (0.11–1.77)
Polyarteritis nodosa 35 o5 1.97 (0.68–5.72) 0 — 16 5 4.31 (1.51–12.3) o5 2.51 (0.33–19.1)
Endocrine
Addison’s disease 196 12 1.05 (0.59–1.89) o5 1.49 (0.55–4.04) 92 6 0.89 (0.39–2.03) o5 0.84 (0.21–3.43)
Graves’ disease 360 21 1.04 (0.66–1.62) 8 1.65 (0.81–3.35) 150 5 0.49 (0.20–1.20) 5 1.26 (0.52–3.06)
Hashimoto’s
thyroiditis
290 17 1.06 (0.65–1.74) o5 1.07 (0.40–2.88) 149 10 0.97 (0.51–1.86) 8 1.98 (0.96–4.08)
Skin
Psoriasis 1543 95 1.07 (0.87–1.33) 19 0.91 (0.58–1.44) 689 57 1.16 (0.88–1.53) 23 1.32 (0.87–2.01)
Alopecia areata 99 6 1.16 (0.50–2.66) o5 0.81 (0.11–5.76) 50 o5 1.23 (0.44–3.42) o5 0.73 (0.10–5.29)
Pemphigus 26 o5 0.69 (0.09–5.13) 0 — 11 0 — 0 —
Localised
scleroderma
178 11 1.11 (0.60–2.06) o5 0.43 (0.06–3.07) 94 5 0.76 (0.31–1.89) 6 2.34 (1.02–5.37)
Discoid lupus
erythematosus
149 5 0.61 (0.25–1.50) o5 0.51 (0.07–3.65) 63 9 2.06 (1.02–4.17) 0 —
Gastrointestinal
Coeliac disease 54 o5 0.63 (0.15–2.60) o5 4.19 (1.30–13.5) 26 o5 0.51 (0.07–3.77) 0 —
Crohn’s disease 316 26 1.43 (0.95–2.15) o5 0.67 (0.21–2.09) 120 14 1.60 (0.91–2.78) 7 2.18 (1.01–4.71)
Ulcerative colitis 504 50 1.72 (1.28–2.31)
c 5 0.72 (0.30–1.74) 229 22 1.33 (0.86–2.07) 7 1.18 (0.55–2.51)
Pernicious anaemia 2008 177 1.57 (1.34–1.84)
c 21 0.74 (0.48–1.14) 886 148 2.38 (1.98–2.86)
c 25 1.11 (0.74–1.67)
Nervous system
Multiple sclerosis 185 7 0.68 (0.32–1.45) o5 0.77 (0.19–3.12) 55 o5 0.55 (0.13–2.22) 0 —
Myasthenia gravis 115 8 1.20 (0.58–2.49) 0 — 54 o5 0.25 (0.04–1.86) o5 2.26 (0.71–7.24)
CI¼confidence interval; OR¼odds ratio; SEER¼Surveillance Epidemiology and End Results. Observations, in which the number of exposed patients or controls is between
one and four, are listed as ‘o5’ to reserve subjects’ anonymity, in accordance with the SEER-Medicare data use agreement. Associations significant at the Po0.05 level are
underlined. For consistency across tables, all ORs are shown to two decimal places (or three significant figures if the OR Z10.0). Nonetheless, we note that many estimates are
based on few exposed cases.
aORs and 95% CIs are adjusted for age (67–69, 70–74, 75–79, 80–84 and 85–99 years), gender, selection year (1987–1996, 1997–1999,
2000–2001, 2002), race (white, non-white) and number of physician claims (0–20, 21–57, 58–127, X128).
bORs and 95% CIs are adjusted for age (67–69, 70–74, 75–79,
80–84 and 85–99 years), gender, selection year (2001, 2002), race (white, non-white) and number of physician claims (0–20, 21–57, 58–127, X128).
cAssociation is
significant at Po0.0005 (Bonferroni correction for 108 comparisons).
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ySeveral case reports have described AML and MDS occurring in
patients with rheumatoid arthritis, mainly after treatment with
azathioprine (Alexson and Brandt, 1977; Kwong et al, 1998) or
methotrexate (Espinosa et al, 2002; Okamoto et al, 2004). However,
non-steroidal anti-inflammatory drugs, used in the treatment of
rheumatoid arthritis and other inflammatory conditions included
in our study, appear to decrease the risk of myeloid leukaemia
(Pogoda et al, 2005), suggesting that their use is unlikely to explain
the excess risk of myeloid malignancies. Unfortunately, we lacked
treatment information and were, therefore, unable to determine
whether the observed increased risks of AML and MDS were
related to therapy.
We also observed an increased risk of AML with systemic lupus
erythematosus, which might be attributed partly to the use of
immune-modulating treatments, such as azathioprine (Alexson and
Brandt, 1977; Kwong et al, 1998). Another systemic autoimmune
condition associated with an increased risk of AML and CML (and
to a lesser extent MDS) was polymyalgia rheumatica. Some studies
have reported polymyalgia rheumatica to occur subsequent to
diagnosis of MDS (Mok et al, 1996; Espinosa et al, 2002), and
polymyalgia rheumatica has been reported to precede AML (Anton,
2007). Giant cell arteritis, a condition closely related to polymyalgia
rheumatica, was more weakly associated with AML in our study.
Among the other autoimmune conditions affecting the cardiovas-
cular system, only systemic vasculitis remained associated with
AML after adjustment for multiple comparisons. To our knowledge,
AML has not been reported in patients with systemic vasculitis,
though large-vessel arteritis has been reported in patients with MDS
(Steurer et al, 2004).
In our study, AIHA significantly increased the risk for all of the
myeloid malignancies. Autoimmune haemolytic anaemia is
considered to be a complication of several lymphoproliferative
disorders (Ekstrom Smedby et al, 2008). Although case reports
describe AIHA with MDS (Giagounidis et al, 2005), AML (Deutsch
et al, 2003) and CML (Arbaje and Beltran, 1990), we found AIHA to
occur antecedent to these diagnoses. Consistent with our findings,
AIHA was found to be associated with an eight-fold increased risk
of AML in a large cohort study in Sweden (Soderberg et al, 2006).
As MDS and MPD are indolent and may be present years before
diagnosis, it is possible that AIHA arose as a result of these
conditions. This explanation is less likely for AML and CML, and it
is possible that AIHA acts late in a causal pathway to promote the
development of these malignancies.
Ulcerative colitis was associated with an increased risk of AML,
in keeping with a Swedish population-based cohort study which
found an 80% increase in ulcerative colitis patients (Askling et al,
2005a). However, other cohort studies found no such relation
between ulcerative colitis and risk of AML (Bernstein et al, 2001;
Winther et al, 2004; Hemminki et al, 2008). Pernicious anaemia
has been reported antecedent to AML (Hsing et al, 1993),
consistent with the association we observed. Dermatomyositis/
polymyositis was associated strongly with CML. Although these
conditions manifest commonly in cancer patients (Stockton et al,
2001), the association with CML remained elevated even when the
5-year period before diagnosis was excluded, indicating that
dermatomyositis/polymyositis may also precede CML.
There are several possible explanations for these associations
with myeloid malignancies. First, as mentioned earlier, certain
treatments for autoimmune conditions, such as azathioprine,
could increase the risk of developing MDS or AML. However,
the associations with AML were not specific to autoimmune
conditions treated with these medications. Second, some auto-
immune conditions could share common genetic predispositions
with myeloid malignancies. For example, carriers of the human
leucocyte antigen-B27 are predisposed to some autoimmune
conditions and AML (Au et al, 2001). Polymorphisms of
interleukin-1 have been associated with several autoimmune
conditions, and polymorphisms in the interleukin 1 receptor
antagonist are associated with AML (Demeter et al, 1996). Finally,
an intriguing possibility is that autoimmune conditions could
infiltrate the bone marrow and cause damage to the myeloid
precursor cells that differentiate into blood cells.
The SMAHRT study has several strengths including the large
number of individuals with myeloid malignancies, the population-
based sampling of cases and the random selection of controls from
the population. The SEER database covers B25% of the US
population (Warren et al, 2002) making our study representative
of the elderly US population. In addition, the availability of
outpatient, inpatient and physician claims allowed us to investigate
the associations between a range of autoimmune conditions and
Table 3 Associations between selected autoimmune conditions and myelodysplastic syndrome and chronic myeloid disorder with exclusions of time
intervals before diagnosis/selection
Time interval before diagnosis/control selection evaluated for autoimmune conditions
41 year 42 years 45 years
Myeloid subtype and autoimmune condition OR (95% CI)
a OR (95% CI)
a OR (95% CI)
a
Myelodysplastic syndrome
Rheumatoid arthritis 1.52 (1.27–1.81) 1.53 (1.27–1.84) 1.52 (1.19–1.92)
Sjo ¨gren’s syndrome 1.78 (1.03–3.07) 1.77 (0.98–3.16) 1.94 (0.91–4.13)
Systemic lupus erythematosus 1.82 (1.04–3.16) 1.87 (1.05–3.32) 1.96 (0.94–4.10)
Polymyalgia rheumatica 1.47 (1.11–1.96) 1.57 (1.17–2.10) 1.53 (1.05–2.22)
Autoimmune haemolytic anaemia 4.12 (1.66–10.2) 4.14 (1.64–11.9) 1.32 (0.16–10.6)
Chronic rheumatic heart disease 1.28 (1.08–1.51) 1.26 (1.05–1.51) 1.16 (0.90–1.49)
Polyarteritis nodosa 4.31 (1.51–12.3) 3.44 (0.90–13.1) 2.78 (0.55–14.1)
Discoid lupus erythematosus 2.06 (1.02–4.17) 1.51 (0.65–3.51) 1.58 (0.56–4.46)
Pernicious anaemia 2.38 (1.98–2.86) 2.20 (1.79–2.70) 1.68 (1.24–2.26)
Chronic myeloproliferative disorder
Autoimmune haemolytic anaemia 11.9 (4.72–30.2) 10.1 (3.27–31.1) 4.02 (0.50–32.5)
Localised scleroderma 2.34 (1.02–5.37) 2.73 (1.18–6.32) 3.47 (1.24–9.77)
Crohn’s disease 2.18 (1.01–4.71) 2.09 (0.91–4.80) 2.00 (0.72–5.50)
CI¼confidence interval; OR¼odds ratio. For consistency across tables, all ORs are shown to two decimal places (or three significant figures if the OR Z10.0). Nonetheless, we
note that many estimates are based on few exposed cases. Associations significant at the Po0.05 level are underlined.
aORs and 95% CIs are adjusted for age (67–69, 70–74,
75–79, 80–84 and 85–99 years), gender, race (white, non-white), number of physician claims (0–20, 21–57, 58–127, X128) and selection year (2001, 2002).
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ymyeloid malignancies. Our study also has some limitations. First, the
small number of cases and controls with some uncommon
autoimmune conditions limit the precision of our estimates, so
cautious interpretation is indicated. Second, as claim files were
utilised in place of a definite diagnosis, autoimmune conditions
which required few physician visits could have been underestimated.
Third, despite our exclusion of a 1-year period before cancer
diagnosis, some autoimmune conditions could have been the result
of the myeloid malignancy. This seems unlikely for AML and CML,
but could explain some associations with the more indolent
conditions, MDS and MPD. Fourth, as MDS and MPD are a
heterogeneous group of diseases, some associations could have been
masked by combining these conditions into one category. Unfortu-
nately, we did not have sufficient sample sizes to investigate risk by
more specific subtypes. Fifth, cases and controls differed according
to some factors, such as race and frequency of Medicare claims,
which could have led to differences in the prevalence of autoimmune
conditions or our ability to detect their presence. However, we
adjusted for these differences in our statistical models. Finally, as
some of the numerous associations investigated may have occurred
by chance, we therefore used a Bonferroni correction to highlight
those associations least likely to be due to chance.
In summary, certain autoimmune conditions were associated
with increased risks of MDS, MPD, CML, and in particular AML,
possibly due to a common genetic predisposition, the effects of
medications used to treat autoimmune conditions, or direct
damage of the bone marrow by autoimmune conditions.
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